A randomly assigned double-blind cross-over study examining the relative anti-Parkinsonian tremor effects of pramipexole and pergolide

European Journal of Neurology

Volumn 12, Issue 1, 2005, Pages 1-8

  Navan, P ^a   Findley, L J ^b   Undy, M B ^c   Pearce, R K B ^a   Bain, Peter G ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAVERING AND REDBRIDGE UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Parkinson's disease; Pergolide; Pramipexole; Randomized controlled trial; Tremor

Indexed keywords

ANTIPARKINSON AGENT; DOMPERIDONE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ORPHENADRINE; PERGOLIDE; PRAMIPEXOLE; PROPRANOLOL; SELEGILINE; TRIHEXYPHENIDYL;

ABDOMINAL PAIN; ADULT; AGED; ANKLE EDEMA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG POTENCY; DYSKINESIA; FEMALE; HALLUCINATION; HEADACHE; HUMAN; LEG PAIN; LETHARGY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP DISORDER; VIVID DREAM; VOMITING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; THIAZOLES; TREMOR;

EID: 12744273153     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.01019.x     Document Type: Article

References (12)

1. Bain PG, Findley LJ, Atchison P et al. (1993). Assessing tremor severity. J Neurol Neurosurg Psychiatry 56:868-873.
2. Celance Data Sheet (1999) Celance (pergolide mesylate) data sheet (1999-2000). In: APBI Compendium of Data Sheets and Summaries of Product Characteristics (1999-2000). London: Datapharm Publications, pp. 734 (and also website: http://emc.medicines.org.uk).
3. Deuschl G, Bain P, Brin M and Ad Hoc Scientific Committee (1998). Consensus statement of the Movement Disorder Society on tremor. Mov Disord 13 (Suppl. 3):2-23.
4. 2 dopamine receptors important for optimal motor functioning in Parkinson's disease? Eur J Neurol 4:3-11.
5. Kunig G, Pogarell O, Moller JC, Delf M, Oertel W (1999). Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol 5:301-305.
6. Mierau J, Schneider FJ, Ensinger H, Chio CL, Lajiness ME, Huff RM (1995). Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. Eur J Pharmacol 290:29-36.
7. Mirapexin Data Sheet (1999) Mirapexin (pramipexole) data sheet, 1999-2000. In: APBI Compendium of Data Sheets and Summaries of Product Characteristics. London: Datapharm Publications, pp. 734 (and also website: http://emc. medicines.org.uk).
8. Navan P, Findley LJ, Pearce RKB, Jeffs J, Bain PG (2003a). A double-blind single dose cross over study of the effects of pramipexole, pergolide and placebo on tremor and UPDRS (III) in Parkinson's disease. Mov Disord 18:176-180.
9. Navan P, Findley LJ, Jeffs AR, Pearce RKB, Bain PG (2003b). Randomly assigned 3-month parallel study of the effects of pramipexole, pergolide and placebo on parkinsonian tremor. Mov Disord 18:1324-1331.
10. Piercey MF, Camacho-Ochoa M, Smith MW (1995). Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 18 (Suppl.):S34-S42.
11. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996). Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists, Eur J Pharmacol 312:35-44.
12. Pogarell O, Gasser T, van Hilten JJ et al. (2002). Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713-720.